I-BET567是一种有效且具有口服活性的 pan-BET 抑制剂，其对 BRD4 BD1 和 BD2 的 pIC50 分别为 6.9 和 7.2，已在肿瘤和炎症小鼠模型中显示有效。

/

2~8℃避光保存，有效期3年。

[1] Humphreys PG,Atkinson SJ,Bamborough P,Bit RA,Chung CW,Craggs PD,Cutler L,Davis R,Ferrie A,Gong G,Gordon LJ,Gray M,Harrison LA,Hayhow TG,Haynes A,Henley N,Hirst DJ,Holyer ID,Lindon MJ,Lovatt C,Lugo D,McCleary S,Molnar J,Osmani Q,Patten C,Preston A,Rioja I,Seal JT,Smithers N,Sun F,Tang D,Taylor S,Theodoulou NH,Thomas C,Watson RJ,Wellaway CR,Zhu L,Tomkinson NCO,Prinjha RK.Design,Synthesis,and Characterization of I-BET567,a Pan-Bromodomain and Extra Terminal(BET)Bromodomain Oral Candidate.J Med Chem.2022 Feb 10;65(3):2262-2287.doi:10.1021/acs.jmedchem.1c01747.Epub 2022 Jan 7.PMID:34995458.